Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites

Molecular and Cellular Biochemistry

Volumn 316, Issue 1-2, 2008, Pages 177-186

  Kramerov, A A ^a   Saghizadeh, M ^a   Caballero, S ^c   Shaw, L C ^c   Li Calzi, S ^c   Bretner, M ^d   Montenarh, M ^e   Pinna, L A ^f   Grant, M B ^c   Ljubimov, A V ^a,b  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Astrocyte; CK2; Diabetes; DRB; Emodin; Endothelial; Hematopoietic stem cell; Neovascularization; Retina; TBB; TBCA

Indexed keywords

4,5,6,7 TETRABROMOBENZIMIDAZOLE; 4,5,6,7 TETRABROMOBENZOTRIAZOLE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; APIGENIN; CASEIN KINASE II; CHRYSIN; DIMETHYLAMINO 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; EMODIN; MESSENGER RNA; OCTREOTIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUERCETIN; TETRABROMOCINNAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MOUSE; NEWBORN; NONHUMAN; PROLIFERATIVE RETINOPATHY; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; CASEIN KINASE II; CATTLE; CELL MOVEMENT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OCTREOTIDE; PROTEIN KINASE INHIBITORS; RETINA; RETINAL NEOVASCULARIZATION;

EID: 50649090911     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9831-4     Document Type: Article

References (35)

1. Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349-368
2. Unger GM, Davis AT, Slaton JW et al (2004) Protein kinase CK2 as regulator of cell survival: Implications for cancer therapy. Curr Cancer Drug Targets 4:77-84
3. Ahmad KA, Wang G, Slaton J et al (2005) Targeting CK2 for cancer therapy. Anticancer Drugs 16:1037-1043
4. Sarno S, Salvi M, Battistutta R, Zanotti G, Pinna LA (2005) Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta 1754:263-270
5. Canton DA, Litchfield DW (2006) The shape of things to come: An emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cell Signal 18:267-275
6. Afzal A, Shaw LC, Ljubimov AV et al (2007) Retinal and choroidal microangiopathies: Therapeutic opportunities. Microvasc Res 74:131-144
7. Duncan JS, Litchfield DW (2008) Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784:33-47
8. Ruzzene M, Penzo D, Pinna LA (2002) Protein kinase CK2 inhibitor 4, 5, 6, 7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364(Pt 1):41-47
9. Wang G, Unger G, Ahmad KA et al (2005) Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol Cell Biochem 274:77-84
10. Yde CW, Frogne T, Lykkesfeldt AE et al (2007) Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett 256:229-237
11. Hamacher R, Saur D, Fritsch R et al (2007) Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol Rep 18:695-701
12. Grant MB, Guay C (1991) Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci 32:53-64
13. Castellon R, Hamdi HK, Sacerio I et al (2002) Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 74:523-535
14. Castellon R, Caballero S, Hamdi HK et al (2002) Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci 43:2758-2766
15. Ljubimov AV, Caballero S, Aoki AM et al (2004) Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci 45:4583-4591
16. Smith LE, Wesolowski E, McLellan A et al (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111
17. Zień P, Bretner M, Zastapiło K et al (2003) Selectivity of 4, 5, 6, 7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. Biochem Biophys Res Commun 306:129-133
18. Kramerov AA, Saghizadeh M, Pan H et al (2006) Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol 168:1722-1736
19. Pagano MA, Meggio F, Ruzzene M et al (2004) 2-Dimethylamino - 4, 5, 6, 7-tetrabromo - 1H-benzimidazole: A novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321:1040-1044
20. Mishra S, Pertz V, Zhang B et al (2007) Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 21:178-180
21. Pagano MA, Poletto G, Di Maira G et al (2007) Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 8:129-139
22. Golub AG, Yakovenko OY, Prykhod'ko AO et al (2008) Evaluation of 4, 5, 6, 7-tetrahalogeno - 1H-isoindole - 1, 3(2H)-diones as inhibitors of human protein kinase CK2. Biochim Biophys Acta 1784:143-149
23. Ljubimov AV (2008) Growth factor synergy in angiogenesis. In: Penn JS (ed) Retinal and Choroidal Angiogenesis. Springer Science+Business Media B.V., p 289
24. Hammes HP, Federoff HJ, Brownlee M (1995) Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1:527-534
25. Pichiule P, Chavez JC, LaManna JC et al (2004) Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem 279:12171-12180
26. Simó R, Carrasco E, García-Ramírez M et al (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2:71-98
27. Nomi M, Miyake H, Sugita Y et al (2006) Role of growth factors and endothelial cells in therapeutic angiogenesis and tissue engineering. Curr Stem Cell Res Ther 1:333-343
28. Folkman J (2007) Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 42:1-11
29. Jo N, Mailhos C, Ju M et al (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036-2053
30. Dorrell MI, Aguilar E, Scheppke L et al (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104:967-972
31. Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614-625
32. Tabruyn SP, Griffioen AW (2007) Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 355:1-5
33. Maloney SC, Godeiro KD, Odashiro AN et al (2007) Current and emerging concepts in the management of neovascular age-related macular degeneration. Cardiovasc Hematol Agents Med Chem 5:147-154
34. Pagano MA, Cesaro L, Meggio F et al (2006) Protein kinase CK2: A newcomer in the 'druggable kinome'. Biochem Soc Trans 34(Pt 6):1303-1306
35. Hessenauer A, Montenarh M, Götz C (2006) Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 22:1263-1270